These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 3097059)

  • 21. The effects of acute and chronic growth hormone (GH) administration on GH secretion in patients with idiopathic GH deficiency.
    Hanew K; Goh M; Sato S; Shimizu Y; Sasaki A; Aida M; Yoshinaga K
    J Clin Endocrinol Metab; 1988 Apr; 66(4):715-21. PubMed ID: 3126213
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Augmentation by propranolol of growth hormone-releasing hormone-(1-44)-NH2-induced growth hormone release in normal short and normal children.
    Chihara K; Kodama H; Kaji H; Kita T; Kashio Y; Okimura Y; Abe H; Fujita T
    J Clin Endocrinol Metab; 1985 Aug; 61(2):229-33. PubMed ID: 2989315
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enhanced growth hormone (GH) responsiveness to GH-releasing hormone after dietary manipulation in obese and nonobese subjects.
    Kelijman M; Frohman LA
    J Clin Endocrinol Metab; 1988 Mar; 66(3):489-94. PubMed ID: 3127415
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of oral glucose administration on spontaneous and growth hormone (GH)-releasing hormone-stimulated GH release in children and adults.
    Valcavi R; Zini M; Volta C; Ghizzoni L; Azzarito C; Bernasconi S; Portioli I
    J Clin Endocrinol Metab; 1994 Oct; 79(4):1152-7. PubMed ID: 7962288
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dual effects of growth hormone (GH)-releasing hormone infusion in normal men: somatotroph desensitization and increase in releasable GH.
    Vance ML; Kaiser DL; Rivier J; Vale W; Thorner MO
    J Clin Endocrinol Metab; 1986 Mar; 62(3):591-4. PubMed ID: 3080467
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunoreactive corticotropin-releasing hormone present in human plasma may be derived from both hypothalamic and extrahypothalamic sources.
    Sasaki A; Sato S; Murakami O; Go M; Inoue M; Shimizu Y; Hanew K; Andoh N; Sato I; Sasano N
    J Clin Endocrinol Metab; 1987 Jul; 65(1):176-82. PubMed ID: 3294879
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cholinergic receptor activation by pyridostigmine restores growth hormone (GH) responsiveness to GH-releasing hormone administration in obese subjects: evidence for hypothalamic somatostatinergic participation in the blunted GH release of obesity.
    Cordido F; Casanueva FF; Dieguez C
    J Clin Endocrinol Metab; 1989 Feb; 68(2):290-3. PubMed ID: 2493023
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Influence of hyperthyroidism on growth hormone secretion.
    Valcavi R; Dieguez C; Zini M; Muruais C; Casanueva F; Portioli I
    Clin Endocrinol (Oxf); 1993 May; 38(5):515-22. PubMed ID: 8330446
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of insulin-induced hypoglycemia on circulating levels of plasma growth hormone-releasing hormone and somatostatin in children.
    Rosskamp R; Becker M; Tegeler A; Klumpp J
    Horm Res; 1987; 27(3):121-5. PubMed ID: 2891599
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of hypothalamic dysfunction in growth hormone (GH)-deficient patients using single versus multiple doses of GH-releasing hormone (GHRH-44) and evidence for diurnal variation in somatotroph responsiveness to GHRH in GH-deficient patients.
    Schriock EA; Hulse JA; Harris DA; Kaplan SL; Grumbach MM
    J Clin Endocrinol Metab; 1987 Dec; 65(6):1177-82. PubMed ID: 3119651
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of recombinant human insulin-like growth factor I administration on the growth hormone (gh) response to GH-releasing hormone in obesity.
    Maccario M; Tassone F; Gianotti L; Lanfranco F; Grottoli S; Arvat E; Muller EE; Ghigo E
    J Clin Endocrinol Metab; 2001 Jan; 86(1):167-71. PubMed ID: 11231996
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In obesity, glucose load loses its early inhibitory, but maintains its late stimulatory, effect on somatotrope secretion.
    Grottoli S; Procopio M; Maccario M; Zini M; Oleandri SE; Tassone F; Valcavi R; Ghigo E
    J Clin Endocrinol Metab; 1997 Jul; 82(7):2261-5. PubMed ID: 9215304
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of intravenous, subcutaneous, and intranasal administration of growth hormone (GH)-releasing hormone-40 on serum GH concentrations in normal men.
    Evans WS; Vance ML; Kaiser DL; Sellers RP; Borges JL; Downs TR; Frohman LA; Rivier J; Vale W; Thorner MO
    J Clin Endocrinol Metab; 1985 Nov; 61(5):846-50. PubMed ID: 3930551
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of central cholinergic neurotransmission enhancement by pyridostigmine on the growth hormone secretion elicited by clonidine, arginine, or hypoglycemia in normal and obese subjects.
    Cordido F; Dieguez C; Casanueva FF
    J Clin Endocrinol Metab; 1990 May; 70(5):1361-70. PubMed ID: 2159483
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aspects of the neuroendocrine control of growth hormone secretion in ageing mammals.
    Müller EE; Cella SG; De Gennaro Colonna V; Parenti M; Cocchi D; Locatelli V
    J Reprod Fertil Suppl; 1993; 46():99-114. PubMed ID: 8100277
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Stimulated growth hormone (GH) secretion in children with delays in pubertal development before and after the onset of puberty: relationship with peripheral plasma GH-releasing hormone and somatostatin levels.
    Saggese G; Cesaretti G; Giannessi N; Bracaloni C; Cinquanta L; Cioni C
    J Clin Endocrinol Metab; 1992 Feb; 74(2):272-8. PubMed ID: 1346143
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diagnosis of growth hormone (GH) deficiency in adults with hypothalamic-pituitary disorders: comparison of test results using pyridostigmine plus GH-releasing hormone (GHRH), clonidine plus GHRH, and insulin-induced hypoglycemia as GH secretagogues.
    Hoeck HC; Vestergaard P; Jakobsen PE; Falhof J; Laurberg P
    J Clin Endocrinol Metab; 2000 Apr; 85(4):1467-72. PubMed ID: 10770183
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Growth hormone (GH) and prolactin responses to repetitive administration of GH-releasing hormone in acromegaly.
    Losa M; Schopohl J; König A; Müller OA; von Werder K
    J Clin Endocrinol Metab; 1986 Aug; 63(2):475-80. PubMed ID: 3088026
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Results of 1-year growth hormone (GH)-releasing hormone-(1-44) treatment on growth, somatomedin-C, and 24-hour GH secretion in six children with partial GH deficiency.
    Rochiccioli PE; Tauber MT; Coude FX; Arnone M; Morre M; Uboldi F; Barbeau C
    J Clin Endocrinol Metab; 1987 Aug; 65(2):268-74. PubMed ID: 3110202
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of oral clonidine, insulin-induced hypoglycemia and exercise on plasma GHRH levels in short-stature children.
    Gil-Ad I; Leibowitch N; Josefsberg Z; Wasserman M; Laron Z
    Acta Endocrinol (Copenh); 1990 Jan; 122(1):89-95. PubMed ID: 2106191
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.